Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM0QZJX)

Drug Name
JNJ-55308942 Drug Info
Indication
Disease Entry ICD 11 Status REF
Anhedonia MB24.2 Phase 1 [1]
Mood disorder 6A60-6E23 Phase 1 [2]
Neuroinflammation 1D0Y Phase 1 [1]
Cross-matching ID
PubChem CID
90408860
TTD Drug ID
DM0QZJX

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
P2X purinoceptor 7 (P2RX7) TT473XN P2RX7_HUMAN Inhibitor [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
P2X purinoceptor 7 (P2RX7) DTT P2RX7 4.744 4.603 3.35 3.248
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Anhedonia
ICD Disease Classification MB24.2
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
P2X purinoceptor 7 (P2RX7) DTT P2RX7 1.11E-06 0.37 0.49
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)